Clinical significance of procalcitonin determination in acute exacerbation of chronic obstructive pulmonary disease

doi:10.3969/j.issn.1673-8640.2016.02.003

Abstract

Abstract:

Objective To investigate the clinical significance of procalcitonin （PCT） in acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods A total of 48 sputum culture positive patients with AECOPD were enrolled as bacterial infection group,and 48 sputum culture negative patients with AECOPD were enrolled as non-bacterial infection group. The PCT was determined,and PCT was determined again in bacterial infection group after treatment for 3,5 and 7 d. Results The level of PCT in bacterial infection group was significantly higher than that in non-bacterial infection group （P<0.01）. In bacterial infection group after treatment for 3,5 and 7 d,PCT levels decreased significantly with statistical significance compared with that before treatment（P<0.01）. The bacterial infection group after treatment for 3 d showed significant difference for PCT compared with that before treatment （P<0.01）. Erythrocyte sedimentation rate（ESR）,white blood cell（WBC）,neutrophil count（NC）and other indicators decreased significantly after treatment for 5 d . In bacterial infection group,2 patients had a continuous increasing of PCT and then died,and non-bacterial infection group all cured. Conclusions PCT is a sensitive index for pulmonary infection in patients with AECOPD,and it also reflects whether infection bacterium is removed or not. It is sensitive to reflect the changes of inflammation degrees and the effect of antimicrobial treatment in the treatment of patients with AECOPD .

Key words: Procalcitonin, Chronic obstructive pulmonary disease, Acute exacerbation, Clinical significance

CLC Number:

R446.62

WANG Yong, FU Shijing, CHEN Rujian, LÜ Wei. Clinical significance of procalcitonin determination in acute exacerbation of chronic obstructive pulmonary disease[J]. Laboratory Medicine, 2016, 31(2): 91-94.

Figures/Tables 2

References 14

[1]	ROTHBERG MB, PEKOW PS, LAHTI M, et al.Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease[J]. JAMA,2010,303(20):2035-2042.
[2]	SETHI S.Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease[J]. Clin Infect Dis,2011,52(Suppl 4):S290-S295.
[3]	BOIXEDA R, RABELLA N, SAUCA G, et al.Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study)[J]. Int J Chron Obstruct Pulmon Dis,2012,7:327-335.
[4]	ALBRICH WC, DUSEMUND F, BUCHER B, et al.Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL)[J]. Arch Intern Med,2012,172(9):715-722.
[5]	朱国民. 降钙素原与C 反应蛋白联合检测在慢性阻塞性肺疾病急性加重期的临床价值[J]. 检验医学,2014,29(12):1246-1247.
[6]	慕月晶,王伟佳,严海忠,等. PCT 检测在全身和局部细菌感染诊断中的临床应用[J]. 检验医学,2015,30(1):17-20.
[7]	HUR M, MOON HW, YUN YM, et al.Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture-positive sepsis[J]. Korean J Lab Med,2009,29(6):529-535.
[8]	LEE JY, HWANG SJ, SHIM JW, et al.Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia[J]. Korean J Lab Med,2010,30(4):406-413.
[9]	LACOMA A, PRAT C, ANDREO F, et al.Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2011, 6: 157-169.
[10]	SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et al.Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial[J]. JAMA, 2009, 302(10): 1059-1066.
[11]	DANIELS JM, SCHOORL M, SNIJDERS D, et al.Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD[J]. Chest, 2010, 138(5): 1108-1115.
[12]	EL MOUSSAOUI R, ROEDE BM, SPEELMAN P, et al.Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies[J]. Thorax, 2008, 63(5): 415-422.
[13]	EL-SOLH AA, VORA H, KNIGHT PR 3RD, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes[J]. Crit Care Med, 2011, 39(6): 1251-1256.
[14]	FALSEY AR, BECKER KL, SWINBURNE AJ, et al.Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note[J]. Int J Chron Obstruct Pulmon Dis, 2012, 7: 127-135.

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
细菌感染组	48	23.4±12.0^*	11.76±2.74^*	11.26±2.54^*	0.365±0.129^*
非细菌感染组	48	11.9±4.3	6.41±1.44	4.42±1.09	0.132±0.056

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
细菌感染组	48	23.4±12.0^*	11.76±2.74^*	11.26±2.54^*	0.365±0.129^*
非细菌感染组	48	11.9±4.3	6.41±1.44	4.42±1.09	0.132±0.056

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
治疗前	48	23.4±12.0	11.76±2.74	11.26±2.54	0.365±0.129
治疗后3 d	48	21.5±10.3	11.16±2.41	10.46±2.49	0.290±0.117^**
治疗后5 d	48	18.3±9.1^*	9.48±2.44^**#	8.03±2.02^**#	0.215±0.100^**#
治疗后7 d	48	14.0±5.7^**#△	7.95±2.16^**#△△	6.53±1.52^**#△△	0.172±0.063^**#△

组别	例数	ESR（mm/h）	WBC计数（×10⁹/L）	NC （×10⁹/L）	PCT（ng/mL）
治疗前	48	23.4±12.0	11.76±2.74	11.26±2.54	0.365±0.129
治疗后3 d	48	21.5±10.3	11.16±2.41	10.46±2.49	0.290±0.117^**
治疗后5 d	48	18.3±9.1^*	9.48±2.44^**#	8.03±2.02^**#	0.215±0.100^**#
治疗后7 d	48	14.0±5.7^**#△	7.95±2.16^**#△△	6.53±1.52^**#△△	0.172±0.063^**#△

[1]	LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531.
[2]	ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364.
[3]	GU Feng, WU Yanfen, ZHAO Xinhui, HOU Zhaoyuan, WANG Zhihong, QI Hualin. Relationship between procalcitonin level and all-cause death in maintenance hemodialysis patients [J]. Laboratory Medicine, 2022, 37(2): 134-140.
[4]	ZHANG Ying, LIU Huiling. Changes of thyroid hormones in patients with COPD and infection and the correlation with low T₃ syndrome [J]. Laboratory Medicine, 2022, 37(11): 1062-1065.
[5]	HE Xuelian, HE Ziyi, LIU Yueyang, YU Yanzhi, ZHANG Siying. Role of line chart model based on peripheral blood-derived inflammation markers in early diagnosis of neonatal septicemia [J]. Laboratory Medicine, 2022, 37(10): 921-927.
[6]	WANG Xiaoqing, PENG Xuemei, LAN Meifeng, PAN Min. Evaluation of MCP-1 combined with CREWS for poor prognosis in patients with AECOPD [J]. Laboratory Medicine, 2022, 37(10): 934-938.
[7]	ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193.
[8]	PAN Xilong, XU Zhiyuan, XIE Feng, LI Dan. Role of procalcitonin in the diagnosis of different sepsis [J]. Laboratory Medicine, 2021, 36(12): 1215-1218.
[9]	ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19 [J]. Laboratory Medicine, 2021, 36(1): 53-56.
[10]	ZHAO Minghai, LI Xin, WEI Dong, LUO Min, ZHANG Yajie, YANG Yiqi, ZHENG Lei. Influence of dry heat inactive treatment for the determination of inflammatory indicators related with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(9): 924-927.
[11]	HUANG Junmin, ZHUANG Xucui, QIU Shuang. Distribution and drug resistance of bacteria in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Laboratory Medicine, 2020, 35(8): 771-774.
[12]	LU Xiufen, HE Zhijun, LIU Qiting, FENG Zhongxin, MA Sheng. Serum procalcitonin and urine endotoxin determinations for guiding CAUTI antimicrobial therapy [J]. Laboratory Medicine, 2020, 35(7): 686-690.
[13]	YAN Peiyi, ZHANG Ji, TU Huanping, ZHANG Li, QIU Yue, ZHANG Fengying, HU Yiwen, JIN Shu. Changes of neutrophil oxidative phagocytosis and related receptors in sputum samples of COPD patients [J]. Laboratory Medicine, 2020, 35(6): 570-577.
[14]	ZHANG Sen, MO Guangzhou, CHEN Zhifeng, LIANG Songrong, LU Yuemei, LIN Kunpei. Predictive value of blood indicators for the long-term mortality of chronic obstructive pulmonary disease [J]. Laboratory Medicine, 2020, 35(2): 112-115.
[15]	LIU Ruilai, SHANG Anquan, GUAN Ming. Diagnostic roles of HNL,PCT and TRAIL in bloodstream infection of patients with hematological diseases [J]. Laboratory Medicine, 2020, 35(12): 1277-1280.